MorphoSys AG
MOR.DENext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MOR.DE. That does not mean none is planned.
Get an email about MOR.DE's next catalysts
Track MorphoSys (MOR.DE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
MOR03087 phase 1 dose escalation
Multiple Myeloma
Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell
Tafasitamab
Diffuse Large B-cell Lymphoma
MOR00208 (formerly Xmab 5574)
Non-Hodgkin Lymphoma
MOR103
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MOR03087 phase 1 dose escalation | Phase 2 | Multiple Myeloma | - | - |
Idelalisib | Phase 2 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
Tafasitamab | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
MOR00208 (formerly Xmab 5574) | Phase 2 | Non-Hodgkin Lymphoma | - | - |
MOR103 | Phase 2 | Rheumatoid Arthritis | - | - |
Frequently asked questions
What is in MorphoSys AG's drug pipeline?β
CatalystAlert tracks 5 drug candidates in MorphoSys AG's (MOR.DE) pipeline across Phase 2. Its lead program is Idelalisib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MorphoSys AG's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for MorphoSys AG (MOR.DE) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track MOR.DE biotech catalysts?β
Add MOR.DE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MorphoSys AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
